Opaleye Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Opaleye Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.45M	Buy	334,437 +222,146	+198%	+$2.16M	0.4%	37
2026 Q1	$1.05M	Buy	+112,291	New	+$977K	0.14%	49
2024 Q3	–	Sell	-345,750	Closed	-$7.26M	–	47
2024 Q2	$7.26M	Buy	345,750 +1,627	+0.5%	+$40.8K	1.66%	18
2024 Q1	$11M	Buy	344,123 +35,623	+12%	+$909K	2.39%	12
2023 Q4	$6.25M	Hold	308,500	–	–	1.66%	17
2023 Q3	$3.93M	Buy	308,500 +86,800	+39%	+$1.45M	1.28%	22
2023 Q2	$4.01M	Sell	221,700 -92,300	-29%	-$1.7M	0.96%	29
2023 Q1	$5.4M	Sell	314,000 -16,000	-5%	-$311K	1.62%	18
2022 Q4	$7.33M	Sell	330,000 -20,700	-6%	-$320K	2.55%	10
2022 Q3	$2.82M	Buy	350,700 +25,700	+8%	+$233K	1.16%	22
2022 Q2	$2.27M	Hold	325,000	–	–	1.02%	26
2022 Q1	$4.91M	Buy	325,000 +96,000	+42%	+$1.51M	1.53%	22
2021 Q4	$5.02M	Buy	+229,000	New	+$5.61M	1.07%	30

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Opaleye Management's FDMT Position: Q2 2026 in Review

Opaleye Management increased its 4D Molecular Therapeutics (FDMT) stake by 198% in Q2 2026, buying an estimated $2.16M and bringing the position to 334,437 shares worth $4.45M. The position accounts for 0.4% of the portfolio, ranked #37.

Opaleye Management first reported a position in FDMT in Q4 2021 and has held it in 13 quarters since. The position peaked at $11M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Opaleye Management held 334,437 shares of 4D Molecular Therapeutics worth $4.45M as of Q2 2026.
Opaleye Management bought 222,146 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.16M.
4D Molecular Therapeutics made up 0.4% of Opaleye Management's portfolio in Q2 2026, its #37 holding.
Opaleye Management first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 13 quarters since.
Opaleye Management's 4D Molecular Therapeutics position peaked at $11M in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.